COVID-19 Symptoms, Testing, and Test Positivity Among Trans Women in the San Francisco Bay Area in 2020-2021.

Abstract

Background: The novel coronavirus (COVID-19) is negatively impacting vulnerable and marginalized communities. Growing research among sexual and gender minority communities shows increased COVID-19 risk and burden due to underlying social structure factors, however, not as much is known about the impact on trans women. Our team gathered data on COVID-19 risk, self-reported prevalence, and testing behaviors as part of an ongoing study of trans women's HIV risk and partnerships to fill this gap in data.

Methods: This is a secondary analysis of data from The Partners Study, a study of HIV risk and transmission among trans women and their sexual partners in the San Francisco Bay Area. We collected COVID-19-related data from 87 trans women from July 2020 to January 2021. Participants were asked whether they were tested for COVID-19, had symptoms, or tested positive for the virus between March 2020 to the time they were screened to participate for a survey interview.

Results: The majority of trans women did not report experiencing COVID-19 symptoms (85.05%, n=74/87) since March 2020. More than half had been tested for COVID-19 (68.9%, n=60/87). Overall, we found a COVID-19 prevalence of 8.33% (n=5/60) among those who received a COVID-19 test.

Public health implications: The COVID-19 prevalence among trans women in our sample was higher than in other gender groups in San Francisco, suggesting that trans women may be disproportionately impacted by this disease. More research is needed to determine the impact of COVID-19 on trans women, and to develop strategies to increase testing and vaccinations among vulnerable communities preventing onward spread.